AGTR1 and metabolic syndrome: This dysregulation was improved when animals suffering MetS were treated with the AT1 receptor blocker candesartan, particularly by the upregulation of anti-inflammatory/anti-oxidative RAS components (i.e., the counterregulatory RAS axis).